Arvinas to Participate in Upcoming Investor Conferences
March 04, 2025 16:05 ET
|
Arvinas Inc.
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
February 24, 2025 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Photys Therapeutics Enters into Exclusive License Agreement with Polymed for Phase 1-Ready IRAK4 Degrader, Furthering its Proximity-based Pipeline and Mission
February 20, 2025 08:00 ET
|
Photys Therapeutics, Incl
Photys Therapeutics exclusively in-licensed Phase 1-ready IRAK4 degrader from Polymed; plan to start Phase 1 later this year for autoimmune indications
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
February 11, 2025 07:00 ET
|
Arvinas Inc.
– Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in...
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
February 03, 2025 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
January 10, 2025 07:00 ET
|
Arvinas Inc.
– Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to initiate in 2025; a second-line Phase 3 combination trial will...
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
January 10, 2025 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Targeted Protein Degradation Industry Forecast to Reach $4.37 Billion by 2034: PROTACs Lead the Charge with Promising Innovations in Oncology
December 20, 2024 07:12 ET
|
Research and Markets
Dublin, Dec. 20, 2024 (GLOBE NEWSWIRE) -- The "Global Targeted Protein Degradation Market by Type, by Application, by End-User, and by Region" report has been added to ResearchAndMarkets.com's...
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
December 13, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors